Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 51Breast 9Tumor-Agnostic 3Other 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Adenocarcinoma 1

Interventions

Carboplatin 8Paclitaxel 7Fluorouracil 7Cisplatin 7atezolizumab 5Trastuzumab 5Pemetrexed 5Oxaliplatin 5Leucovorin 5Bevacizumab 5pembrolizumab 4Gemcitabine 4Capecitabine 4Albumin-Bound Paclitaxel 4Surveys and Questionnaires 3Observation 3Leuprolide 3Irinotecan 3Glutamine 3Drug Therapy 3Docetaxel 3Dexamethasone 3130-nm albumin-bound paclitaxel 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2enzalutamide 2Surgical Procedures, Operative 2Standard of Care 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Leuprolide × Tumor-Agnostic × Clear all
NCT01442246 2024-09-19

Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

UNICANCER

Phase 3 Active not recruiting
700 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00380406 2017-04-05

PROOF

Ottawa Hospital Research Institute

Phase 3 Completed
30 enrolled
Tumor-Agnostic

Neoplasms

NCT01011751 2015-07-30

Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma

Takeda

Phase 3 Completed
311 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡